Chemomab Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	7.56	6.07	9.29	13.52	15.19
Short-Term Investments	2.8	8.2	10.49	26.37	45.98
Cash & Short-Term Investments	10.37	14.27	19.78	39.89	61.16
Cash Growth	-27.34%	-27.89%	-50.41%	-34.77%	422.83%
Other Receivables	3.06	0.26	0.29	0.46	0.18
Receivables	3.06	0.26	0.29	0.46	0.18
Prepaid Expenses	-	1.44	0.75	1.31	1.35
Restricted Cash	-	0.08	0.08	0.08	-
Total Current Assets	13.43	16.04	20.9	41.74	62.69
Property, Plant & Equipment	0.18	0.54	0.7	0.59	0.7
Other Long-Term Assets	0.21	0.39	0.56	0.73	0.96
Total Assets	13.81	16.96	22.15	43.06	64.35
Accounts Payable	0.49	0.67	0.52	1.69	1.34
Accrued Expenses	0.99	2.44	4.25	4.94	1.21
Current Portion of Leases	-	0.12	0.08	0.12	0.11
Total Current Liabilities	1.48	3.22	4.84	6.75	2.65
Long-Term Leases	-	0.21	0.32	0.09	0.24
Total Liabilities	1.48	3.43	5.15	6.84	2.89
Additional Paid-In Capital	123.95	116.16	105.68	101.26	97.64
Retained Earnings	-111.62	-102.62	-88.68	-63.82	-36.17
Treasury Stock	-	-	-	-1.22	-
Total Common Equity	12.33	13.54	17	36.22	61.47
Shareholders' Equity	12.33	13.54	17	36.22	61.47
Total Liabilities & Equity	13.81	16.96	22.15	43.06	64.35
Total Debt	-	0.32	0.39	0.21	0.34
Net Cash (Debt)	10.37	13.94	19.39	39.68	60.82
Net Cash Growth	-25.65%	-28.10%	-51.13%	-34.76%	439.64%
Net Cash Per Share	1.63	3.11	6.60	13.95	23.45
Filing Date Shares Outstanding	7.19	4.71	3.55	2.76	2.85
Total Common Shares Outstanding	7.19	4.71	3.55	2.76	2.85
Working Capital	11.95	12.82	16.06	34.99	60.04
Book Value Per Share	1.71	2.87	4.79	13.11	21.56
Tangible Book Value	12.33	13.54	17	36.22	61.47
Tangible Book Value Per Share	1.71	2.87	4.79	13.11	21.56
Machinery	-	0.5	0.5	0.5	0.43
Leasehold Improvements	-	0.01	0.01	0.02	0.02

Updated Mar 19, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q